Clinical Trials Logo

Metastatic Colorectal Cancer clinical trials

View clinical trials related to Metastatic Colorectal Cancer.

Filter by:

NCT ID: NCT01858662 Terminated - Clinical trials for Metastatic Colorectal Cancer

Study Comparing Pathological Responses Observed on Colorectal Cancer Metastases Resected After Preoperative Treatment Combining Cetuximab With FOLFOX or FOLFIRI in RAS and B-RAF WT Tumors

Start date: January 2014
Phase: Phase 2
Study type: Interventional

To analyze the pathological tumor response on resected colorectal cancer metastases after preoperative treatment with cetuximab combined with FOLFOX or FOLFIRI regimen in a prospective cohort (RAS and B-RAF WT tumors) and to correlate this response with patient's outcome.

NCT ID: NCT01767857 Terminated - Clinical trials for Metastatic Colorectal Cancer

A Phase III Study of Xilonix in Patients With Advanced Colorectal Cancer

XCITE
Start date: March 31, 2013
Phase: Phase 3
Study type: Interventional

The purpose of this study is to determine if the True Human Monoclonal antibody Xilonix (MABp1) can prolong the life of colorectal carcinoma patients that are refractory to standard therapy.

NCT ID: NCT01718808 Terminated - Clinical trials for Metastatic Colorectal Cancer

Cetuximab for Elderly Patients With mCRC

Start date: November 2012
Phase: Phase 2
Study type: Interventional

OBJECTIVE: The objective of the trial is to judge on the benefit obtained by an upfront cetuximab treatment delivered as monotherapy or as part of a combination treatment with capecitabine in vulnerable elderly patients selected for V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog (KRAS) wild-type and B-type Raf kinase (BRAF) wild-type metastatic colorectal cancer (mCRC).

NCT ID: NCT01669720 Terminated - Clinical trials for Metastatic Colorectal Cancer

Adjuvant Aflibercept for Metastatic Colorectal Cancer

C261
Start date: December 2012
Phase: Phase 2
Study type: Interventional

The main purpose of this study is to evaluate if aflibercept can reduce the chance that metastatic (spread of) colorectal cancer can grow back after finishing standard treatment. The study will also look at the side effects of aflibercept and the effect on quality of life.

NCT ID: NCT01605318 Terminated - Rectal Cancer Clinical Trials

Study of Labetuzumab Govitecan in Participants With Metastatic Colorectal Cancer

Start date: February 12, 2013
Phase: Phase 1/Phase 2
Study type: Interventional

The goal of this clinical study is to determine the dosing and safety of labetuzumab govitecan (formerly known as IMMU-130; hMN-14-SN38, antibody-drug conjugate) in participants with colorectal cancer.

NCT ID: NCT01532804 Terminated - Clinical trials for Metastatic Colorectal Cancer

2nd-line Treatment of Metastatic Colorectal Cancer

BEVATOMOX
Start date: July 28, 2011
Phase: Phase 2
Study type: Interventional

This phase 2 trial aims to evaluate the continued use of bevacizumab with raltitrexed and oxaliplatin combination versus FOLFOX6 plus bevacizumab in patients with metastatic colorectal cancer whose disease has progressed after irinotecan-based chemotherapy.

NCT ID: NCT01507545 Terminated - Colorectal Cancer Clinical Trials

Morphotek Investigation in Colorectal Cancer: Research of MORAb-004 (MICRO)

Start date: March 27, 2012
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate whether therapy with MORAb-004 is effective and safe in the treatment of metastatic, colorectal cancer.

NCT ID: NCT01280643 Terminated - Clinical trials for Metastatic Colorectal Cancer

Combination Chemotherapy and Cetuximab or Bevacizumab in Treating Patients With Metastatic Colorectal Cancer

Start date: March 2010
Phase: N/A
Study type: Interventional

RATIONALE: Drugs used in chemotherapy, such as fluorouracil, leucovorin calcium, oxaliplatin, capecitabine, and irinotecan hydrochloride, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) and giving the drugs in different combinations may kill more tumor cells. Monoclonal antibodies, such as bevacizumab and cetuximab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Giving combination chemotherapy together with bevacizumab or cetuximab may kill more tumor cells. PURPOSE:To evaluate the use of standard (KRAS) and experimental (thymidine phosphorylase, ERCC1 and BRAF) tumor testing can aid in selecting chemotherapy regimens

NCT ID: NCT01109615 Terminated - Clinical trials for Metastatic Colorectal Cancer

Pemetrexed and Gemcitabine for Treatment Resistant Patients With Metastatic Colorectal Cancer and KRAS Mutations

PG
Start date: April 2010
Phase: Phase 2
Study type: Interventional

This study aims to investigate the efficacy and safety of the combination of pemetrexed and gemcitabine in heavily pre-treated, chemotherapy resistant colorectal cancer patients with KRAS mutations.

NCT ID: NCT01008475 Terminated - Clinical trials for Metastatic Colorectal Cancer

EMD 525797 in Combination With Cetuximab and Irinotecan in K-ras Wildtype Metastatic Colorectal Cancer

POSEIDON
Start date: October 2009
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to assess the safety and clinical activity of the experimental drug EMD 525797 (study drug), a monoclonal antibody targeting α v integrins, in combination with irinotecan and cetuximab in K-ras wildtype metastatic colorectal cancer patients.